Although previous studies suggest objective responses with BRAF and MEK inhibitors in the majority of patients with BRAF-mutant melanoma, data also suggest that acquired resistance limits response durations with these drugs. Preclinical data suggest that intermittent dosing of these agents may delay such resistance. To determine whether intermittent dosing of BRAF/MEK inhibitors improved progression-free survival (PFS) in patients with advance BRAF-mutant melanoma when compared with continuous dosing, researchers randomized patients on 8-weeks of continuous BRAF/MEK inhibitor therapy to either further continuous therapy or intermittent dosing on a 3-week-off, 5-week-on schedule. Median PFS was statistically significantly longer (9 months from randomization) with continuous dosing when compared with intermittent dosing (5.5 months). At a median follow-up of 2 years, median overall survival was 29.2 months in both groups. In the continuous treatment group, 77% of patients discontinued treatment due to disease progression, compared with 84% in the intermittent treatment group.
Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.
August 27, 2020
March 25, 2020
Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer.
August 6, 2020
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- ENDO: 2020ENDO 2020 Annual Conference has been canceled due to COVID-19. Here are highlights of emerging data that has still been released. Keep an eye out for ENDO Online 2020, which will take place from June 8 to 22.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.
- ASCO 2019The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.